Lupin Rolls Out Spiriva Generic In US, Looks To Take Back From Respimat
Indian Firm Bagged First FDA Approval For Tiotropium DPI In June
Executive Summary
Indian respiratory player Lupin has begun shipping its US generic version of Boehringer Ingelheim’s Spiriva HandiHaler, amid plans both to capture share from the originator’s follow-on soft mist inhalation brand and continue development of its own Respimat rival product.
You may also be interested in...
Lupin And Mark Cuban Shake Hands On Spiriva Alliance In US
Self-labelled ‘disruptor’ Mark Cuban has brought on board yet another high-demand prescription drug, following a recent deal for biosimilar Humira.
Generics Bulletin Explains: The Changing US Generics Market
After a couple of years of heavy downwards pressure on US generics prices, prominent off-patent companies have pointed to a change in the pricing environment as several factors combine to reduce price erosion. Meanwhile, some firms are benefiting from first generic launches as others exit the market altogether, while injectables shortages continue to loom large.
Spiriva Generic Must Deliver To Maintain Exit Margin Estimates At Lupin
The performance of its recently-launched Spiriva generic will be crucial for Lupin’s future performance, as it forecasts year-end exit margins in the high teens.